Related Experiment Videos
[Cardiodynamic changes induced with dilazep in chronic coronary insufficiency]
Giornale Italiano Di Cardiologia
|January 1, 1980
Summary
Dilazep at 300 mg daily reduced pre-ejection period and blood pressure in chronic coronary disease patients. Lower doses showed no significant cardiovascular effects, indicating a dose-dependent response for dilazep
Area of Science:
- Cardiology
- Pharmacology
Context:
- Chronic coronary disease management requires effective therapeutic agents.
- Assessing the cardiovascular effects of drugs like dilazep is crucial.
Purpose:
- To evaluate the effects of dilazep on systolic intervals, heart rate, and blood pressure in patients with chronic coronary disease.
- To determine the dose-dependent cardiovascular response to dilazep.
Summary:
- Dilazep administration (300 mg/day) in 16 patients with chronic coronary disease led to a reduction in pre-ejection period (PEP) and a decrease in both systolic and diastolic blood pressure.
- In contrast, 12 patients receiving a lower dose (150 mg/day) showed no significant alterations in systolic intervals or blood pressure.
- These findings suggest dilazep exhibits a positive inotropic effect and moderate vasodilatory action at a 300 mg daily dosage.
Impact:
- The study highlights the potential of dilazep as a therapeutic option for chronic coronary disease at specific dosages.
- Results indicate a clear dose-response relationship for dilazep's cardiovascular effects.
- Further research may explore the long-term efficacy and safety of dilazep in this patient population.